ACM
PCRX icon

Anfield Capital Management’s Pacira BioSciences PCRX Stock Holding History

Anfield Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-11
Closed -$1K – 124
2021
Q3 		$1K Buy
+11
New +$634 ﹤0.01% 119

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Anfield Capital Management's PCRX Position: Q4 2021 in Review

Anfield Capital Management sold out of Pacira BioSciences (PCRX) in Q4 2021, closing a stake of 11 shares — an estimated $1K sold.

Anfield Capital Management first reported a position in PCRX in Q3 2021 and held it in 1 quarter. The position peaked at $1K in Q3 2021. 276 funds tracked by Wall St. Rank hold PCRX as of Q4 2021.

  • Anfield Capital Management reported no remaining Pacira BioSciences position as of Q4 2021 after selling out during the quarter.
  • Anfield Capital Management sold 11 Pacira BioSciences shares in Q4 2021, an estimated $1K.
  • Anfield Capital Management first reported a position in Pacira BioSciences in Q3 2021 and held it in 1 quarter.
  • Anfield Capital Management's Pacira BioSciences position peaked at $1K in Q3 2021.
  • 276 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2021.

Based on Anfield Capital Management's 13F filing for Q4 2021, filed 3 Feb 2022.